Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(50.0%)
Phase 3
2(33.3%)
N/A
1(16.7%)
6Total
Phase 2(3)
Phase 3(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03598218Not ApplicableCompleted

Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma

Role: collaborator

NCT04350190Phase 2Completed

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Role: collaborator

NCT03612219Phase 2Unknown

Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma

Role: collaborator

NCT02434614Phase 3Unknown

Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Role: collaborator

NCT03130270Phase 2Unknown

Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma

Role: collaborator

NCT01479504Phase 3Unknown

A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Role: collaborator

All 6 trials loaded